文献速递前列腺增生与排尿功能障碍

Revi植入式胫神经调控三年疗效与安全性:OASIS关键研究

Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study.
PubMed 文献 · J Urol · 2026-04-13

36个月时79%为治疗应答者(急迫性尿失禁发作减少≥50%),6至36个月应答率分别为78%和79%,95%满意,82%报告“好多了”或“好很多”,无器械或操作相关严重不良事件。

要点

  • 36个月时79%患者为治疗应答者(急迫性尿失禁发作减少≥50%)。
  • 6至36个月疗效持久,应答率分别为78%和79%。
  • 无器械或操作相关严重不良事件至36个月。

核心结论

  • Revi植入式胫神经调控系统在女性急迫性尿失禁中显示有意义且持久的疗效、高患者满意度和良好安全性至3年。

研究设计与样本

  • FDA批准关键试验OASIS研究,151例女性植入Revi系统,主要疗效和安全性终点分别在6和12个月评估,后延长随访至36个月。

主要发现

  • 76%(90/119)完成36个月评估,其中79%(71/90)为治疗应答者(急迫性尿失禁发作减少≥50%,基于3天排尿日记)。
  • 6至36个月应答率分别为78%和79%,疗效持久。
  • 95%(83/87)报告治疗满意,82%(74/90)基于患者整体改善印象量表报告“好多了”或“好很多”。
  • 至36个月无器械相关或操作相关严重不良事件报告。

关键数值与推荐

  • 治疗应答定义为急迫性尿失禁发作减少≥50%(基于3天排尿日记)。
  • 36个月时79%(71/90)为治疗应答者。
  • 6个月和36个月应答率分别为78%和79%。
  • 95%(83/87)报告治疗满意。
  • 82%(74/90)报告“好多了”或“好很多”。

临床怎么用

  • Revi系统可为女性急迫性尿失禁提供持久且安全的植入式胫神经调控治疗选择。
  • 患者可通过外部 wearable 设备个体化调控刺激。
  • 长期随访显示高满意度和良好安全性,支持临床应用于传统非难治性患者。

局限性

  • 36个月评估完成率为76%(90/119),存在随访丢失。
  • 研究仅纳入女性患者。
  • 原文未报告随机对照比较结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Revi is a novel implantable tibial neuromodulation system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence. The Revi System (manufactured by BlueWind Medical) is the first FDA-cleared implantable neuromodulation device that can be used in traditionally nonrefractory patients. Three-year follow-up results from the pivotal FDA-approval trial, the OASIS Study, are presented. MATERIALS AND METHODS: The Revi System was implanted in 151 women. The primary efficacy and safety end points were assessed at 6 and 12 months, respectively; thereafter, participants were consented to extend follow-up to 3 years for assessments of long-term treatment durability and safety. RESULTS: Ninety-three percent (140/151) completed the 12-month study, and 85% (119/140) met screening criteria and consented to the 36-month extension study. Ninety participants (76%, 90/119) completed the 36-month assessment, and 79% (71/90) were therapy responders (≥50% reduction in urgency urinary incontinence episodes, demonstrated on a 3-day voiding diary). Sustained therapeutic responses were reported, with durable effectiveness between 6 and 36 months (response rates of 78% and 79%, respectively). Notably, 95% (83/87) reported therapeutic satisfaction, and 82% (74/90) reported feeling "much better" or "very much better" based on the Patient Global Impression of Improvement scale. No device-related or procedure-related serious adverse events were reported through 36 months. CONCLUSIONS: In women with urgency urinary incontinence, Revi-an implantable tibial neuromodulation system powered by a patient-controlled, external wearable ankle device-showed meaningful and durable efficacy, high patient satisfaction, and an excellent safety profile through 3 years.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Amundsen CL, Sutherland SE, Heesakkers JPFA, et al. Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study. J Urol. 2026. PMID: 41973947. doi:10.1097/JU.0000000000005062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。